Avita Medical (RCEL) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Avita Medical (RCEL) is Neutral.

The composite score behind that read is +0.06, weighing +0.21 of bullish evidence against -0.28 bearish.

Avita Medical last closed at $13.21, -0.90% on the session.

Against the IVW growth benchmark the position is -1.70% over the forecast window.

The read is built from 15 underlying insights — 3 bullish and 12 bearish.

Agreement across those insights is 80%.

10 graded predictions for RCEL so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Avita Medical in the 98th percentile on return on equity, where 100 is best.

Avita Medical is classified under Health Care / Biotechnology, with a market capitalisation of $412.26M.

StockMap tracks Avita Medical as the 192nd largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Avita Medical ranks 63rd of 381 in the group, against a group median of -0.08.